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Objective
To describe how clinicians conceptualised equipoise in the
PART (Partial prostate Ablation vs Radical prosTatectomy in
intermediate-risk unilateral clinically localised prostate cancer)
feasibility study and how this affected recruitment.
Subjects and Methods
PART included a QuinteT Recruitment Intervention (QRI)
to optimise recruitment. Phase I aimed to understand
recruitment, and included: scrutinising recruitment data,
interviewing the trial management group and recruiters
(n = 13), and audio-recording recruitment consultations
(n = 64). Data were analysed using qualitative content
and thematic analysis methods. In Phase II,
strategies to improve recruitment were developed and
delivered.
Results
Initially many recruiters found it difﬁcult to maintain a
position of equipoise and held preconceptions about which
treatment was best for particular patients. They did not feel
comfortable about approaching all eligible patients, and when
the study was discussed, biases were conveyed through the
use of terminology, poorly balanced information, and direct
treatment recommendations. Individual and group feedback
led to presentations to patients becoming clearer and enabled
recruiters to reconsider their sense of equipoise. Although the
precise impact of the QRI alone cannot be determined,
recruitment increased (from a mean [range] of 1.4 [0–4] to
4.5 [0–12] patients/month) and the feasibility study reached
its recruitment target.
Conclusion
Although clinicians ﬁnd it challenging to recruit patients to a
trial comparing different contemporary treatments for
prostate cancer, training and support can enable recruiters to
become more comfortable with conveying equipoise and
providing clearer information to patients.
Keywords
equipoise, feasibility, qualitative, recruitment, randomised
controlled trial, #PCSM, #ProstateCancer
Introduction
Patients with intermediate-risk localised prostate cancer
are usually offered radical prostatectomy (RP) or external
beam radiotherapy with a view to curing the cancer,
although these can result in substantial urinary, bowel,
and sexual function side-effects [1]. Partial ablation (PA)
techniques have been developed to target the cancer,
preserving the rest of the prostate, and thus aiming to
reduce treatment side-effects. These techniques include
high-intensity focused ultrasound (HIFU), cryotherapy,
photodynamic therapy, brachytherapy, and radiofrequency
© 2018 The Authors
BJU International | doi:10.1111/bju.14432 BJU Int 2018
published by John Wiley & Sons Ltd on behalf of BJU International. www.bjui.org wileyonlinelibrary.com
This is an open access article under the terms of the Creative Commons Attribution-NonCommercial License, which permits use,
distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes.
interstitial tissue ablation. A systematic review reported
that PA rarely causes signiﬁcant morbidity and appears to
have a reduced impact on quality of life, although
ﬁndings are based on a few experienced centres and
data from non-randomised studies on oncological
effectiveness or impact on functional outcomes and
quality of life [2].
The PART (Partial prostate Ablation vs Radical
prostaTectomy; ISRCTN 99760303) feasibility study aimed to
recruit 80 men with intermediate-risk unilateral clinically
localised prostate cancer (deﬁned as Gleason grade score 7
(3+4 or 4+3), >4 mm cancer core length, PSA level ≥20 ng/
mL, clinical ≥T2b disease) to a randomised controlled trial
(RCT) comparing PA or RP. HIFU was identiﬁed as the
most promising PA technology at the time of trial
development [3]. However, delivering an RCT of PA against
RP was anticipated to be particularly challenging because of
the likelihood of strong views amongst clinicians and patients
about two very different treatments [4].
Given that recruitment was anticipated to be difﬁcult, an
embedded QuinteT Recruitment Intervention (QRI) aimed
to understand, and subsequently optimise, recruitment [5].
The QRI was developed initially for the Prostate Testing
for Cancer and Treatment (ProtecT) trial and has been
implemented subsequently in 25 RCTs [6]. The QRI
identiﬁed several issues that affected recruitment in
PART, including organisational barriers and recruiter
difﬁculties with explaining the trial to potential patients
[7]. The present article focuses on how clinicians
conceptualised equipoise in PART, how this changed
during the QRI and in their presentations of information
to patients, and what lessons could be learned for future
trials.
Subjects and Methods
Study Design
The QRI involved two iterative phases: Phase I, which
sought to identify and understand recruitment difﬁculties
(through analysis of screening logs, interviews with trial
staff, and audio-recording consultations where PART was
discussed with patients); and Phase II, which implemented
strategies to optimise recruitment and informed consent.
The study is reported according to qualitative reporting
guidelines (Table S1). Ethics approval was provided by the
NHS Health Research Authority National Research Ethics
Service (NRES) Committee London – Camden and Kings
Cross (14/LO/0640). Written informed consent was
provided by all participants.
Data Collection
Data were collected in three ways:
Interviews
Semi-structured interviews were conducted with members of the
Trial Management Group (TMG) and healthcare professionals
who were involved in recruitment. Separate topic guides were
developed for the TMG and recruiters (Appendix S1) to ensure
coverage of overall study issues (TMG) and recruitment
(recruiters), with sufﬁcient ﬂexibility to allow for new issues to
emerge. Interviews were transcribed verbatim, checked against
the audio-recording for accuracy, and transcripts were imported
into NVivo (version 10, QSR International).
Data were analysed by D.E. using techniques of constant
comparison derived from grounded methodology, which aims
to generate new theories about phenomena that develop from,
or are ‘grounded’ in, the data as they are collected and
compared with existing ﬁndings to identify similarities and
differences [8]. Emerging themes were discussed with J.L.D.
with reference to the raw data. Equipoise was considered to
be present if recruiters conveyed that patients would not be
advantaged or disadvantaged if they were to receive either
procedure (as far as existing evidence would dictate) [9]. Any
instances where clinicians described certainty or uncertainty
around treatment superiority, or any discussion/practices that
suggested that treatments were equivalent or one would be
better or worse for the patient were coded.
Recorded Recruitment Consultations
Healthcare professionals recruiting to PART were requested
to audio-record appointments where they provided
information to eligible patients about the study and treatment
options. Recordings were transcribed verbatim, and for this
analysis, selected parts related to equipoise issues were
extracted. These were analysed as described above for
interviews, with the addition of some of the techniques of
focused conversation analysis to identify and document
aspects of informed consent and information provision that
was unclear, disrupted or hindered recruitment [5].
Patient Pathway Through Eligibility and
Recruitment
Screening logs from all centres were examined regularly for
information on the number of patients screened, eligible,
approached, and randomised [10], to provide contextual
information about recruitment in clinical centres and across
the study.
Results
Interviews
The QRI team approached 23 participants to take part
(including members of the TMG, and representatives from
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each recruiting site). A total of 13 one-to-one interviews
were conducted between July and November 2015 by two
researchers (D.E. and P.W.). The ﬁnal sample included 12
recruiters (four of whom were members of the TMG) and
one non-recruiting TMG member. Interviews lasted a mean
(range) of 43 (31–53) min.
Recorded Consultations
In all, 64 recruitment appointments with 54 patients were
audio-recorded (ten patients had two consultations
recorded) between September 2015 and April 2017: 24 as
part of QRI Phase I and 40 after feedback in Phase II.
Consultations lasted a mean (range) of 27 (10–42) min. In
all, 12 different recruiters led the consultations. Audio-
recordings were obtained from four recruiting sites
(Table 1).
Quotations are provided to support the results, and
distinctions are made between data from interviews and
recorded consultations. Quotes were anonymised to ensure
conﬁdentiality.
Phase I: Understanding Recruitment Challenges
Views on the Study Design
In interviews, there was clear enthusiasm for the PART study,
and HIFU was described as an ‘exciting’ and ‘promising’
alternative to radical procedures. Some urologists commented
that comparing only one form of PA vs one radical treatment
(surgery) might exclude patients who expressed preferences
for treatment options outside PART (such as radiotherapy or
brachytherapy). However, there was consensus that more data
were available for HIFU. The ProtecT trial had not yet been
published and so RP was deemed the most appropriate
comparator.
Interview, Recruiter 1:‘I think this trial is needed
because there has been a lot of hype or buzz about
HIFU and focal therapy for some years now.’
Previous Recruitment Experience
Recruitment to RCTs was acknowledged to be challenging,
particularly discussing concepts such as uncertainty and
randomisation. Many participating clinicians had not
received training for their role as recruiters, with the exception
of four recruiters who had participated in the ProtecT study
and appeared more comfortable with the concept of
randomisation and how to convey uncertainty to potential
trial patients:
Interview, Recruiter 2: ‘I haven’t, personally, been
responsible for recruiting to trials [. . .] I have no idea
whether HIFU’s going to work or not, so it makes it
very difﬁcult to know how much of that information to
tell patients.’
Interview, Recruiter 15: ‘I think we need to be conﬁdent
on our uncertainty, and you know, I’ve learned a lot by
being involved in ProtecT [. . .] We acknowledge that
there are uncertainties in the decision-making, which is
why we run clinical trials.’
Discomfort with the Eligibility Criteria
Recruiters often described that they felt that some patients,
although fulﬁlling the study’s eligibility criteria, were more
suitable for a particular treatment option. This meant that
not all eligible patients were necessarily invited to be enrolled
in PART. When patients were approached, the question of
whether they were eligible for participation affected how
clinicians communicated with patients. Examples of this are
shown in Table 2.
Recruiter Bias
In interviews, those who had not received support or training
for their role as recruiters sometimes expressed strong
preferences for a particular treatment. Advocates of RP
expressed concerns that HIFU would not remove all of the
cancer, whereas those who favoured HIFU expressed concerns
Table 1 Overview of data collected from centres.
Site Number of
recruiters
Number with
previous
training
Number
interviewed
Number of
recordings
before
feedback
Overview of
feedback
Number of recordings
after feedback
Centre 1 5 1 5 9 Group feedback (93), tips document, individual
feedback to one recruiter
3
Centre 2 3 0 2 2 Group feedback, tips document 0
Centre 3 3 0 2 6 Group feedback (93), tips document, individual
feedback to one recruiter
17
Centre 4 3 0 1 7 Group feedback (92), tips document, individual
feedback to one individual (twice)
20
Centre 5 3 3 2 0 Group feedback (92), tips document 0
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that surgery would be over-treating cancer and compromising
quality of life unnecessarily. Consequently, recruiters found it
difﬁcult to express equipoise (Table 3).
Consultations showed that these beliefs were conveyed to
patients. There were several instances where the concept of
uncertainty was not introduced and biased terminology was
used, such as ‘gold standard’ RP and ‘experimental’ HIFU.
Recruiters also provided unbalanced accounts of the
procedures (e.g. discussing primarily the advantages of HIFU
and the disadvantages of RP). Sometimes direct treatment
recommendations were provided. Following this, patients
tended to express clear preferences for a speciﬁc treatment
and declined participation in PART.
Consultation, Recruiter 2: ‘If you have surgery, with the
kind of disease you have, you’d almost certainly not die
of prostate cancer.’ (Patient declines PART, opts for RP)
Consultation, Recruiter 9: ‘You’ve then the option of
partially destroying the part of the prostate where the
cancer is, and in your case, it’s on the left-hand side.
That’s called ‘focal destruction’. [. . .] It’s all done very
cleverly [. . .] It is a potentially attractive option [. . .] It’s
quite favourable.’ (Patient declines PART, opts for HIFU)
Between January and November 2015 (during the ﬁrst phase
of the QRI), 15 men had been recruited and the mean
(range) number of patients agreeing to be randomised was
1.4 (0–4) patients/month, with a conversion rate (the
numbers of eligible men invited to join PART who then went
on to be randomised) of 20% (15/75). The lead site had
recruited most of these, whilst some sites had not recruited
any patients in that time (Table 4).
Optimising Recruitment
Summary of Training
In November 2015, the QRI team presented the ﬁndings of
Phase I to the Chief Investigator and TMG, and strategies to
improve recruitment and informed consent were developed
(Table 5). These included group feedback, individual feedback,
and the production of ‘tips’ documents (Appendix S2). Group
sessions were interactive, with open discussions encouraged.
Overall QRI feedback and training focussed on:
• Ways in which recruiting to RCTs differs to standard
practice.
• The lack of randomised evidence comparing RP with
HIFU.
• The extent to which there was community equipoise (i.e. by
demonstrating the conﬂicting biases for the treatment arms).
• Examples of how recruiter beliefs could inﬂuence patient
preferences.
• The importance of exploring preferences to ensure men
were making a fully informed decision.
Table 2 Recruiter perceptions of the PART eligibility criteria.
Inclusion criterion,
according to protocol
Examples of recruiter discomfort
Gleason grade score
7 (3+4 or 4+3)
Interview, Recruiter 12: ‘I was just marginally uncomfortable because he had a 4+3 and he was 50 years old and it was quite a signiﬁcant
volume of tumour. I just found myself thinking, “Do you know what? I wonder if you’d be better off having a radical prostatectomy.”’
Interview, Recruiter 9: ‘3+4’s, I think they are maybe the best ones to treat with HIFU, where they’ve got mainly pattern 3, but a bit of pattern
4. I think you can be pretty conﬁdent that you’re going to wipe out that pattern 4 when you do the treatment.’
High volume Gleason grade
score 6 (>4 mm cancer
core length)
Interview, Recruiter 15: ‘If somebody had all of the cores from one side, let’s say every single core from one side was involved from a mapping
biopsy and it was involved with like 80% of four plus three but the other side is completely clear. In theory he is a PART candidate. But
actually maybe he is better off with a prostatectomy.’
Life expectancy ≥10 years Interview, Recruiter 9: ‘I think for some patients let’s just say in their 70s, let’s say between 70 and 75, I have absolutely no problem saying,
“Surgery or radiotherapy, it doesn’t matter which one you have. Just choose the one for which the conduct of therapy and the side effects
feels best to you”. For the people perhaps between 65 and 70 I’m sort of in the same opinion but perhaps slightly leaning towards surgery. For
the under 65s I really think that surgery is probably better because of the life expectancy they probably have and the risk of failure going into
the long-term and the long-term burden of even fairly mild toxicity from radiotherapy.’
Table 3 Recruiter perceptions of PART treatment options.
Recruiter Examples of recruiter bias
Recruiter 6 ‘There’s very few patients with whom I still have equipoise with as to whether they should have HIFU or prostatectomy.’
Recruiter 9 ‘It’s just whether that a prostatectomy is over treating their cancer. . . and I’ve got to be honest with them.’
Recruiter 1 ‘They are compromising their cancer treatment by taking the risks that we’re only treating one part of the prostate. And so there might be another part of the
prostate which has some prostate cancer in. So that they understand that, after I’ve told them.’
Recruiter 12 ‘I think of the patients who have been suitable for both surgery and HIFU I have to say I probably steered them towards HIFU whenever they have been
suitable.’
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Changes to Recruitment and Informed Consent
Phase II of the QRI began in November 2015, and continued
for the remainder of recruitment. During this time, a mean
(range) of 4.5 (0–12) patients/month were randomised and
the conversion rate increased from 20% (15/75) to 42% (67/
161). Furthermore, after the initial intervention in December,
several centres (rather than predominately Site 1) began
recruiting consistently (Table 3). Analysis of the recordings
available after feedback highlighted changes in the ways
recruiters discussed the study and treatment options
(Table 6).
Discussion
The PART study aimed to evaluate the feasibility of
recruiting men with intermediate-risk prostate cancer to
HIFU or RP. A QRI was integrated to identify and address
barriers to recruitment. Early in the feasibility study, in
Phase I of the QRI, recruiters without previous experience of
recruitment found the concept of equipoise difﬁcult and
often disclosed their views about the most suitable treatment
for patients. In Phase II of the QRI, several strategies were
implemented to enable recruiters to discuss their views
about the treatments and the trial, and then support them
to convey uncertainty and equipoise to patients more clearly.
There was an increase in recruitment from 1.4 patients/
month in Phase I of the QRI to 4.5 patients/month in Phase
II. After the ﬁrst QRI intervention in December, centres
began recruiting consistently. There was also evidence to
suggest that the QRI had inﬂuenced clinicians’ practices and
led to clear presentations of equipoise to patients. Whilst it
is not possible to determine the precise impact that the QRI
had on recruitment, this suggests it had a positive impact.
The PART study randomised a total of 82 men, showing
that it is feasible to recruit to an RCT of RP vs HIFU, and
paves the way for a deﬁnitive and potentially practice-
changing large Phase III RCT, currently in preparation.
Previous research has shown that recruiters can ﬁnd the dual
roles of clinician and researcher conﬂicting [11]. Their
experience can lead them to favour one treatment in general
or for patients with particular disease characteristics or health
states. A recent study of six trials showed that even when
recruiters intended to convey equipoise to patients, they often
failed to do so or provided unbalanced information, with
some undermining equipoise with recommendations [9]. A
systematic review indicated that didactic-based learning may
not necessarily be most effective for recruitment training [12].
In PART, training and support was delivered in a way that
encouraged discussion and collaborative decision-making
about equipoise and uncertainty, so that recruiters could ﬁnd
their own position of equipoise and then understand how
they could communicate this more clearly to trial patients.
The present study indicates that it is possible to change how
recruiters present information to patients. Moreover, the
conﬁdence of recruiters who received training from ProtecT
[13] suggests that the effect of this support may be sustained.
The main strength of the present research was the use of
qualitative methods to provide insights into clinician
Table 4 Recruitment by each centre.
Centre 2015 2016 2017
January–March April–June July–
September
October–
December
January–
March
April–June July–
September
October–
December
January–
March
Site 1 4 5 2 4 4 2 5 2 9
Site 2 Activated 05/15
Site 3 Activated 06/15 1 2 5 1 1
Site 4 Activated 10/15 1 2 3 4
Site 5 Activated 11/15 2 7 4 2 10
Total 4 5 2 8 6 16 10 7 24
Table 5 Summary of PART recruitment interventions.
Date PART recruitment interventions
November 2015 Preliminary QRI ﬁndings discussed with Chief Investigator
December 2015 Full descriptive report on recruitment issues sent to
Chief Investigator
December 2015 Two-part recruitment session at Collaborator’s meeting
December 2015 Group feedback session at Centre 3
December 2015 Recruitment e-mail sent to all recruiters
December 2015 Recruitment newsletter sent to all recruiters
February 2016 Tips document sent to each recruiter
February 2016 Recruitment newsletter sent to all recruiters
February 2016 Individual feedback meeting with recruiter from Centre 1
March 2016 Group meeting at Centre 2 to discuss recruitment
March 2016 Group feedback session at Centre 3
March 2016 Website updated to include patient information about PART
April 2016 Recruitment newsletter sent to all recruiters
April 2016 Group feedback session at Centre 1
April 2016 Group feedback session at Centre 5
May 2016 Recruitment newsletter sent to all recruiters
May 2016 Individual feedback meeting with recruiter from Centre 4
May 2016 Individual feedback meeting with recruiter from Centre 3
Funding variation – July 2016–September 2016
September 2016 Recruitment newsletter sent to all recruiters
October 2016 Recruitment e-mail sent to all recruiters
October 2016 Group feedback to Centre 3
January 2017 Recruitment e-mail to all recruiters
January 2017 Individual feedback with recruiter from Centre 3
January 2017 Group feedback session at Centre 1
February 2017 Recruitment e-mail sent to all recruiters
March 2017 Individual feedback with recruiter from Centre 4
© 2018 The Authors
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equipoise in real consultations. The QRI adopted a range of
qualitative data collection methods to gain an in-depth
understanding of recruitment processes, how the trial was
presented, and how patients were responding to the trial. It
was also possible to compare what was intended (in
interviews) with what was actually expressed in consultations.
Thus, interviews showed participants’ intention to be neutral,
but the consultations showed ways in which they
unintentionally steered patients towards particular treatments.
Recorded consultations also enabled us to compare how
recruiters with or without previous experience presented
equipoise before and then after training. The opportunity to
feedback ﬁndings quickly to change practices was a key
strength, highlighting the applied nature of the QRI [14].
Table 6 Before and after feedback.
Recruiter Before feedback After feedback
Consultation:
Recruiter: ‘I think you are most suitable for focal treatment with HIFU
[. . .] I think the research study that I was going to be talking about is
probably not relevant for you.’
Consultation:
Patient: ‘What do you think?’
Recruiter: ‘I’ve been a consultant for years and I sit here telling men what’s going
on, telling them they’ve got cancer, they ask me what treatment we go for, and
I try and help them and steer them in the direction, but, at the end of the day,
I have to sometimes stop and say, “Actually, there isn’t really any evidence that
this treatment is better than that one because there have never been any proper
trials comparing properly treatment A with treatment B. To get proper results,
you have to actually do it in a randomised way.” There is a study called PART,
that we’re very much involved with. . .’
Recruiter 9 Consultation:
Patient: ‘What would be your advice? Which treatment, in this particular
case?’
Recruiter: ‘I think that surgery or radiotherapy, for someone who is
young and ﬁt like you, with slightly more bulky disease, would be more
appropriate. So, I don’t think the trial is right for you.’
Consultation:
Recruiter: ‘I don’t think that there’s an obvious, “You must go one way or the
other.” The reality is, there’s such a lack of evidence, we just don’t know. I’m a
fan of both treatments, if that makes sense, and regularly I’m referring people
for both sorts of treatments [. . .] The more I have these discussions and the
more I reﬂect on it all, it does make me think, “You know what [name] a lot of
what you say is based on very little evidence.” We don’t really know whether
treatment A is better than treatment B.’
Recruiter 12 Interview:
Recruiter: ‘I think of the patients who have been suitable for both
surgery and HIFU I have to say I probably steered them towards HIFU
whenever they have been suitable. Partly I am trying to build my
experience and partly it is a less toxic treatment. It ﬁts in with the ﬁrst
idea of do no harm. You also have the ability to save the situation.’
Consultation:
Recruiter: ‘I have to say it’s very difﬁcult. I feel that both treatments would be
very good for you. I could sit here and sing the praises of each modality of
treatment actually and it’s difﬁcult to say which would be best in your situation.
And partly, if you’re looking for something in the short-term that was good,
then you might say, “Well, HIFU has less side effects up front.” But in the
longer term there’s uncertainty about whether you need repeat treatment, on-
going monitoring, all of that uncertainty. We don’t know what the long-term
results are – 10, 15, 20 years – we don’t know the results of focal treatment.
Whereas with surgery we know those true outcomes, but we know also that it
carries a greater burden of side effects. I can’t tell you which of those packages
is best overall, only this kind of study will tell us that.’
Consultation:
Patient: ‘I think my concern, I mean I was interested in HIFU because it
carries the least possible side effects. I know it’s in its infancy but I
think-’
Recruiter: ‘A bit beyond infancy I would say but yes.’
Patient: ‘About 15 years?’
Recruiter: ‘I think HIFU has been probably around for that sort of time.
Focal therapy treatment has probably been going from around 2007/8,
something like that. We’ve got quite a lot of outcome which is going to
be published. [. . .] We have some conﬁdence that the results will be
okay otherwise we wouldn’t be doing it.’
Consultation:
Patient: ‘HIFU sounds like an attractive idea.’
Recruiter: ‘I think the important thing to realise is that we also think it’s an
attractive idea. . .but it’s very important in what we do to establish evidence to
really know that attractive ideas turn out to be good ideas [. . .] The only
problem is that we don’t have long term follow up. We certainly don’t have this
randomised evidence. There is a body of opinion which says that in your case,
intermediate-risk prostate cancer, we don’t really know which is better; surgery
with whole gland therapy or focal therapy.’
Recruiter 2 Consultation:
Recruiter: ‘I can tell you why I think surgery is good and what’s great
about surgery, but I’m not here to tell you what is great or not great
about radiotherapy or HIFU.’
Consultation:
Recruiter: ‘I don’t know [if HIFU is as good as surgery] because we haven’t done
the study yet. But the data would support that it appears to be as good, yes. But
I can’t answer that question in terms of cancer control. What I can say for sure
is that if you had the HIFU, you’re likely to have a quicker recovery. You’ll be
out of hospital quickly. Generally people are less tired afterwards, less fatigued
and they tend to have a quicker recovery from the HIFU treatment. And it
probably has less impact on erections. It certainly has less impact on
incontinence.’
Consultation:
Recruiter: ‘I think surgery would be a good treatment choice for you.’
Consultation:
Recruiter: ‘In terms of advice [. . .] it’s not for me to tell you what treatment to
have [. . .] I’m here to tell you what are the pros and cons of different
treatments.’
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The present study has several limitations. It was conducted in
one trial with an observational design, and so ﬁndings should
be interpreted with caution. It is not possible to evaluate the
causal effects of the QRI in this small study, but a formal
evaluation of the effectiveness of QRIs implemented to date
on the numbers of eligible patients approached and
conversion rates will be presented in due course. It is
challenging to quantify changes in recruiter communication
with patients. Innovative methods have been developed to
assess the balance of information provision [15] and provide
evidence of participant understanding [16]. It will be
important in future work to develop ways to quantify the
effects of the training and support. In terms of sampling, the
views of those who agreed to be interviewed may not be
representative of all clinicians (for instance, the site leads may
have been more enthusiastic about the study than other
clinicians at their centre). However, even amongst these,
diverse opinions were expressed. Many research nurses were
also unavailable for interviews or did not respond to the QRI
researcher. Furthermore, despite QRI encouragement and
support, sites did not regularly record all consultations (as
has been the case in previous QRIs [14,17–19]). This
sometimes made it difﬁcult to provide tailored and speciﬁc
feedback, limiting the potential impact the QRI might have
had.
In summary, recruiters can ﬁnd it difﬁcult to enrol patients
in a trial comparing very different treatment arms, such as
PA and RP. This research suggests that these challenges can
be overcome by targeted training and support to enable
recruiters to become more comfortable with the concept of
uncertainty and then have conﬁdence to approach eligible
patients and present equipoise clearly to facilitate informed
decision-making and trial participation.
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